ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,930Medicare Part D Prescriptions Filled, Including Refills

Rank: 223 out of 890

$736K Total Retail Price of All Prescriptions

Rank: 125 out of 890

466 Patients Receiving at Least One Drug in Part D
76%Patients 65 Years and Older
36% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Louisiana
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

4% of this provider’s 466 patients filled at least one prescription for a schedule three drug, compared to an average of 15%.

Risky Drugs to Seniors

2% of this provider’s 7,926 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

38% of this provider’s prescriptions were for brand-name drugs, compared to an average of 25%.

Prescription Price

$74 was the average price of a prescription from this provider, compared to $55 among peers.

Prescriptions per Patient

21 is the average number of prescriptions (including refills) per patient, compared to an average of 21.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Louisiana
AMLODIPINE BESYLATE 631 534 1 1
SIMVASTATIN 473 389 2 5
METOPROLOL SUCCINATE 420 370 3 17
SYNTHROID 401 364 4 53
CRESTOR 384 264 5 25
HYDROCHLOROTHIAZIDE 319 263 6 9
ATORVASTATIN CALCIUM 276 234 7 13
METFORMIN HCL 240 222 8 6
ALENDRONATE SODIUM 218 203 9 38
LISINOPRIL 205 139 10 4
METOPROLOL TARTRATE 179 133 11 15
PANTOPRAZOLE SODIUM 166 115 12 34
DIOVAN 159 109 13 33
OMEPRAZOLE 142 111 14 8
NIASPAN 135 81 15 212
POTASSIUM CHLORIDE 121 83 16 11
CLONIDINE HCL 120 93 17 35
ZOLPIDEM TARTRATE 108 67 18 19
FUROSEMIDE 105 81 19 7
QUINAPRIL HCL 102 88 20 116
JANUVIA 97 74 21 59
WARFARIN SODIUM 97 75 21 24
LOSARTAN POTASSIUM 93 69 23 29
BYSTOLIC 93 66 23 86
SPIRIVA 86 47 25 66
BENICAR HCT 80 77 26 166
AMLODIPINE BESYLATE-BENAZEPRIL 77 65 27 41
BENAZEPRIL HCL 72 46 28 44
RANITIDINE HCL 70 58 29 49
LOSARTAN-HYDROCHLOROTHIAZIDE 69 55 30 57
LOVAZA 68 59 31 120
LEVOTHYROXINE SODIUM 65 65 32 2
PLAVIX 62 52 33 42
CLOPIDOGREL 61 57 34 28
LISINOPRIL-HYDROCHLOROTHIAZIDE 61 45 34 21
ENALAPRIL MALEATE 61 58 34 56
DIOVAN HCT 60 53 37 48
ALLOPURINOL 59 43 38 31
SERTRALINE HCL 57 52 39 26
ATENOLOL 57 51 39 23
NEXIUM 57 39 39 14
AMITRIPTYLINE HCL 57 30 R 39 43
HYDROCODONE-ACETAMINOPHEN 56 46 S3 43 3
AZITHROMYCIN 56 41 43 37
ADVAIR DISKUS 56 39 43 52
FLUTICASONE PROPIONATE 54 40 46 39
PRAVASTATIN SODIUM 53 46 47 10
BENICAR 50 49 48 180
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 8, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.